[Therapeutic effects of risedronate on Paget's disease of bone].
Paget's disease of bone (PDB) is a chronic disorder characterized by focal abnormalities of bone turnover. The characteristic feature of PDB is excessive osteoclastic bone resorption coupled to increased and disorganized bone formation. Although PDB is rare in Japan, it is quite common in most European countries, except for Scandinavia. The recommended regimens for bisphosphonates use in various parts of the world. Calcitonin and etidronate are approved by the Ministry of Health, Labour and Welfare in Japan to treat PDB. Risedronate is currently under development for use in the treatment of PDB in Japan.
Takata
Shinjiro
S
The University of Tokushima Graduate School, Institute of Health Biosciences, Department of Orthopedics.
D000368:Aged; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010001:Osteitis Deformans / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D000068296:Risedronic Acid
D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid